Good morning :)
$
₹
BioRestorative Therapies Inc

BioRestorative Therapies Inc

BRTX

NASDAQ
Asset Logo

BioRestorative Therapies Inc

BRTX

NASDAQ
$1.544.81% (-0.07)
$
₹
$1.544.81% (-0.07)
High
—
—
Low
—
—
Returns
—
—
Loading...
1D
1W
1M
3M
6M
1Y
3Y
5Y
Max

Healthcare

Biotechnology

Micro Cap

With a market cap of $2.2M the stock is ranked 6141

Key Metrics

Key Metrics

PE TTM
PE TTM

Close price divided by the earnings per share for the trailing twelve months

—
PB
PB

Close price divided by the book value per share at the end of the most recent quarter

1.16
EPS TTM
EPS TTM

Net profit earned per share over the trailing twelve months (sum of the last 4 quarters)

$-20.98
PEG Ratio
PEG Ratio

Price-to-Earnings (P/E) ratio divided by the forecasted annual earnings per share (EPS) growth rate over the next five years

0
Profit Margin
Profit Margin

Net profit divided by the total revenue for the most recent financial year

0%
Dividend Yield
Dividend Yield

Annual dividend per share for the trailing twelve months divided by the close price

—

Analyst Ratings & Forecast

Analyst Ratings & Forecast

Detailed Forecast Detailed Forecast 

Based on 2 analysts reports

Buy
1 analyst
Hold
1 analyst
Sell
0 analyst

Price Upside

+18418.52%

Earnings Growth

-730.19%

Rev. Growth

-13.82%

See Detailed Forecast

Company Profile

Company Profile

BioRestorative Therapies, Inc. develops therapeutic products and medical therapies using cell and tissue protocols primarily involving adult stem cells. The company develops programs related to the treatment of disc/spine disease and metabolic disorders. Its products pipeline comprises BRTX-100, a lead cell therapy candidate formulated from autologous cultured mesenchymal stem cells collected from the patient's bone marrow, as well as used for the non-surgical treatment of painful lumbosacral disc disorders or as a complimentary therapeutic to a surgical procedure; and ThermoStem, a cell-based therapy candidate to target obesity and metabolic disorders using brown adipose derived stem cells to generate brown adipose tissue. The company also operates a commercial biocosmeceutical platform. In addition, it provides investigational curved needle device to deliver cells and/or other therapeutic products or material to the spine and discs, and other parts of the body. The company was formerly known as Stem Cell Assurance, Inc. and changed its name to BioRestorative Therapies, Inc. in August 2011. BioRestorative Therapies, Inc. is headquartered in Melville, New York.
BioRestorative Therapies, Inc. develops therapeutic products and medical therapies using cell and tissue protocols primarily involving adult stem cells. The company develops programs related to the treatment of disc/spine disease and metabolic disorders. Its products pipeline comprises BRTX-100, a lead cell therapy candidate formulated from autologous cultured mesenchymal stem cells collected from the patient's bone marrow, as well as used for the non-surgical treatment of painful lumbosacral disc disorders or as a complimentary therapeutic to a surgical procedure; and ThermoStem, a cell-based therapy candidate to target obesity and metabolic disorders using brown adipose derived stem cells to generate brown adipose tissue. The company also operates a commercial biocosmeceutical platform. In addition, it provides investigational curved needle device to deliver cells and/or other therapeutic products or material to the spine and discs, and other parts of the body. The company was formerly known as Stem Cell Assurance, Inc. and changed its name to BioRestorative Therapies, Inc. in August 2011. BioRestorative Therapies, Inc. is headquartered in Melville, New York.

Peers

Compare with peers Compare with peers 

Peers

Compare with peers Compare with peers 
AbbVie Inc
ABBV
AbbVie Inc
P/E Ratio
80.68
80.68
1Y Return
24.94%
24.94%
Buy Reco %
80.00
80.00
Amgen Inc
AMGN
Amgen Inc
P/E Ratio
27.28
27.28
1Y Return
51.04%
51.04%
Buy Reco %
35.29
35.29
Gilead Sciences Inc
GILD
Gilead Sciences Inc
P/E Ratio
—
—
1Y Return
29.23%
29.23%
Buy Reco %
78.57
78.57
Vertex Pharmaceuticals Inc
VRTX
Vertex Pharmaceuticals Inc
P/E Ratio
29.90
29.90
1Y Return
23.96%
23.96%
Buy Reco %
81.25
81.25
Moderna Inc
MRNA
Moderna Inc
P/E Ratio
—
—
1Y Return
662.28%
662.28%
Buy Reco %
21.73
21.73
Compare with Peers

Forecast

Forecast

Price

Revenue

Earnings

Price Forecast

Price Forecast

Higher price growth forecast versus trailing 3-year CAGR
Compares analyst forecast growth with historical annualized growth.

The 12-month consensus target implies 18418.52% growth, versus a trailing 3-year CAGR of -65.00%.

2026
Current$1.62Baseline
Analyst Target - 1 year
Target$300+18418.52%

All values in $

202220232024202520262027$83.59$165.73$247.86Target+18418.52%
2026
Current$1.62Baseline
Analyst Target - 1 year
Target$300+18418.52%

All values in $

Revenue Forecast

Revenue Forecast

Lower revenue growth forecast versus trailing 3-year CAGR
Compares analyst forecast growth with historical annualized growth.

The next fiscal year's mean estimate implies -13.82% growth, versus a trailing 3-year CAGR of 44.27%.

2025
Current$359.7Baseline
Forecast for Dec 2026
High$310-13.82%
Average$310-13.82%
Low$310-13.82%

All values in $ Thousand

20212022202320242025202646119.8145.8401359.7Low-13.82%Average-13.82%High-13.82%
2025
Current$359.7Baseline
Forecast for Dec 2026
High$310-13.82%
Average$310-13.82%
Low$310-13.82%

All values in $ Thousand

Earnings Per Share Forecast

Earnings Per Share Forecast

2025
Current$-1.59Baseline
Forecast for Dec 2026
High$-13.2-730.19%
Average$-13.2-730.19%
Low$-13.2-730.19%

All values in $

202120222023202420252026-17-5.11-3.51-1.25-1.59Low-730.19%Average-730.19%High-730.19%
2025
Current$-1.59Baseline
Forecast for Dec 2026
High$-13.2-730.19%
Average$-13.2-730.19%
Low$-13.2-730.19%

All values in $

Financials

Financials

Income

Balance Sheet

Cash Flow

0.3
-2.6
0
-3
0
-3.2
0
-2.1
Q2 2025
Q3 2025
Q4 2025
Q1 2026
Revenue
Net Income
Financial YearQ4 2023Q1 2024Q2 2024Q3 2024Q4 2024Q1 2025Q2 2025Q3 2025Q4 2025Q1 2026
Total Revenue0.010.030.080.230.040.020.300.010.010.02
Net Income-2.82-2.22-4.02-1.09-1.63-5.33-2.65-3.03-3.20-2.15
Net Profit Margin-14638.43%-6352.15%-4521.39%-467.21%-3778.63%-21359.19%-875.78%-25748.11%-16365.48%-9298.25%
See CostsAll values in $ Million

Peers

Peers & Comparison

Peers & Comparison

Comparing 2 stocks from
HealthcareBiotechnology

Valuation

Returns

Forecast

ScreenerCompare valuation on Screener
StockPE TTMPE TTMPBPBPEG RatioPEG Ratio
BioRestorative Therapies Inc -1.160
AbbVie Inc80.6850.450.53
Amgen Inc27.2817.562.28
ScreenerCompare valuation on Screener

Price Comparison

Price Comparison

Compare BRTX with any stock or ETF
Compare BRTX with any stock or ETF
Comparing from
BRTX
ABBV
AMGN
Loading...

Frequently asked questions

  1. BioRestorative Therapies Inc (BRTX) share price today is $1.54 as of October 27, 2026 at 1:29 AM IST. The stock touched a day high of $1.63 and a day low of $1.49.

  2. BioRestorative Therapies Inc stock trades on NASDAQ under the ticker symbol BRTX.

  3. BioRestorative Therapies Inc's market capitalization is $2.23M as of October 27, 2026 at 1:29 AM IST.

  4. BioRestorative Therapies Inc's price-to-earnings (P/E) ratio is N/A as of October 26, 2026.

  5. BioRestorative Therapies Inc's price-to-book (P/B) ratio is 1.16 as of October 26, 2026.

  6. Yes, You can buy BioRestorative Therapies Inc shares from India through Tickertape, via our partnership with ViewTrade IFSC under the IFSCA Global Access framework, subject to RBI’s Liberalised Remittance Scheme (LRS) limits.

  7. Indian investors can buy BioRestorative Therapies Inc shares in three steps: 1. Search BioRestorative Therapies Inc on the Tickertape app and tap Invest. 2. Complete your one-time digital KYC. 3. Fund your account and buy from as low as $1 via fractional shares.

  8. Since BioRestorative Therapies Inc trades in USD, an Indian investor's INR returns depend on both the stock's price movement and the USD-INR exchange rate. If the rupee depreciates against the dollar, INR returns are boosted beyond the stock's USD return; if the rupee appreciates, INR returns are reduced.

  9. Indian investors can start investing in BioRestorative Therapies Inc (BRTX) shares from as little as $1 through fractional ownership on Tickertape - for example, $10 buys approximately 6.485 shares at the current price of $1.54.

Loading...